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This article describes the human microbiota and microbiomes’ strategic role in 
personalizing health and disease management, which is rapidly demanding 
diligent regulatory science and policy action to ascertain confidence and trust 
among consumers, patients, and healthcare providers. The authors discuss why 
establishing harmonized processes and standards to better understand the 
baseline healthy microbiota is essential to development of strategies for 
nutrition and clinical applicability. They conclude that, given the complexity of 
issues, a well-orchestrated, multistakeholder approach is advisable for the best 
chance of success. 
 
Introduction 
Traditional paradigms for healthcare product development are significantly 
challenged as we enter an era of new tools (e.g., CRISPR, RNAi, “omics” 
diagnostic technologies, in silico trials, digitization, apps, and wearables) and 
face new or shifting targets, such as human microbiota/microbiomes, 
consumer-patient continuum, and shifts from disease management to health-
preserving strategies. In addition to current population-based approaches, 
rapidly evolving science and technologies provide the potential for personalizing 
nutrition and medicine, leading toward highly individualized, precision therapies 
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and preventive medicine. These developments are opening new avenues to 
tackle rare (orphan) and common noncommunicable and communicable 
diseases.1-3  
 
Targeting microbiomes on and in humans as part of developing health- and 
disease-focused solutions for the human organism opens a broad perspective 
for preventative, as well as therapeutic, interventions. The human microbiota ‒ 
at times considered a virtual organ constituted of eubacteria, as well as archaea, 
filamentous fungi, yeasts, protozoa, viruses ‒ cohabits our bodies and may hold 
the key to many aspects of maintaining good health. These aspects include 
having an impact on digestion and boosting the immune system, cognitive 
functions, and even longevity. Multiple facts and causalities have yet to be 
established or refined because it is still not clear what defines a healthy 
microbiome and what causal relationships exist between diet, health, disease, 
and respective disturbances.4,5 
 
These opportunities and challenges require significant and acute out-of-the-box 
rethinking, as well as open communication and sharing of, and access to, data. It 
requires collaboration between multiple stakeholders from regulatory 
authorities, academia, manufacturers, healthcare professionals, payers, and 
patients to establish, interpret, and implement appropriate regulations and 
healthcare policies.6 
 
Innovating regulatory science 
Evolving scientific and innovative technological tools, processes, and respective 
terminologies, allow us to study and establish new personalized, precision, 
tailored, or bespoke approaches to preventing and treating diseases. All those 
elements will result in increased intervention efficiency compared with more 
general, less precise population-based approaches. With a focus on the human 
microbiome, a thorough knowledge of the types and ratios of microbes is 
needed before microbiome science can be incorporated into routine clinical 
practice.7 There have been multiple efforts to establish the baseline(s) and 
standards for comparison of an individual’s microbiome or metagenome to 
expand the knowledge base of what a ’normal’ microbiome constitutes. These 
efforts still focus mostly on specific subsets of the issue, such as the Genomic 
Standards Consortium8 on reporting (meta)genomic sequences, the Critical 
Assessment of Metagenomic Interpretation on computational tools used in 
metagenomic research,9 or the International Human Microbiome Standards on 
standardization of procedures to study the gut microbiome.10 Standardization is 
shown to be an issue for all microbiome research, as evidenced recently by 
MicrobiomeSupport on food systems microbiomes.11-13 
 
It is essential to define which factors determine a healthy state of a particular 
microbiome and its resilience. Study results may lead to divergent conclusions, 
depending on the kinds of methods or procedures used. For example, various 
DNA extraction methods or the relative abundance of species (i.e., eubacteria, 
archaea, filamentous fungi, yeasts, protozoa, viruses) may favor different 
organisms and bias outcomes. Hence, agreements on human reference 
microbiomes and standardization of the various steps in microbiome analyses 




are needed for analyses linked to health, disease, or gender, or for comparing 
the clinical effects related to nutrition or drugs. More accurate, higher-
throughput data accrual, and the ability to organize, store, access, and share 
data sets via comparable bioinformatics pipelines are needed to increase 
comparability and reproducibility of results.14,15 
 
Standardization of the microbiome research field starts with the general 
adoption of standardized reference reagents. The UK’s National Institute for 
Biological Standards and Control for microbiome analysis by next-generation 
sequencing DNA reference reagents were used to develop a first set of 
reference reagents and a four-measure framework for evaluating bioinformatics 
tool and pipeline bias. These can act as global working standards and will be 
evaluated as candidate World Health Organization International Reference 
Reagents.16 
 
There has been progress in defining reference genomes reflecting the human 
gastrointestinal microbiome. A unified sequence catalog of more than 200,000 
genomes and 171 million protein sequences of the human gut microbiome have 
been generated. Of note is that more than 70% of the species in the catalog 
have not yet been cultured, and 40% of the proteins have unknown functions. 
The catalog will be instrumental in gaining a deeper mechanistic understanding 
of the human gut microbiomes.17 
 
With further standardization and the identification of reference metagenomes, 
the overall aim of a planned European coordination and support action18 is to 
structure the field of microbiome research as related to human health and to 
reach global agreement, among scientific institutions, regulatory authorities, 
industry, and funders, on human reference microbiomes in an effort to:  
 
• standardize the different steps in human microbiome studies  
• define healthy states in and on the human body 
• contribute to collaborative synergistic collection of microbiome data to 
improve coherence and reduce overlap 
• integrate metagenomics and human microbiome references into other 
multilateral cooperation areas or personalized medicine approaches 
 
There is a strategic role and potential of the human microbiome in personalizing 
health and disease management. A growing body of evidence suggests that 
noncommunicable diseases (NCDs) are associated with unbalanced dietary 
patterns and subsequent disturbances in the gut microbiome (dysbiosis), now 
recognized as an important biological interface between human genetics, 
lifestyle, and environmental conditions. With new research insight as a result of 
high throughput omics technologies in the current postgenomic era, there is 
growing interest in the functioning of the gut microbiome and the potential for 
developing innovative applications and personalized health solutions that target 
the microbiome.19,20 
 
There is a need for diligent regulatory and policy action, considering the rapid 
pace of science and technology development and the application potential of 




these fields. A range of microbiome-related, or pre- and probiotics-based, 
products and derived active compounds (postbiotics) are already available, 
ranging from certain foods, to food supplements, including fermented foods or 
fermentation products, to fecal microbiota transplants (FMT). As with all 
healthcare-related products for nutritional or medicinal purposes, quality, 
safety, efficacy, and fitting the intended use or health claim must be 
demonstrated. However, current regulatory guidance is limited, because no 
consolidated national or global regulatory frameworks are applicable.21 The 
need for an international dialogue between multiple stakeholders has been 
recognized for harmonizing the scientific standardization and technological 
development, as has the need for microbiome product regulation.22 There is an 
ongoing dialogue among the Intestinal Microbiome-based Medicines European 
Task Group,23 the International Probiotics Association,24 and the Microbiome 
Therapeutics Innovation Group.25 
 
The US Food and Drug Administration (FDA) has published guidance dedicated 
to FMT26 and live-biotherapeutic products.27 To further microbiome-related 
discussion and research, an interagency Microbiome Working Group was 
created as well, with FDA and National Institutes of Health experts. As Rousseau 
and colleagues have noted,28 FMTs illustrate the variety of regulatory statuses 
potentially applicable to microbiome-related health products, some of which 
may conflict with existing regulations applicable to tissues and cells as defined in 
the EU and the US as “human material.”29,30 When administered for difficult-to-
treat, potentially life-threatening Clostridium difficile infection, FMT meets the 
US definition of a biological product.31 The EU Commission, without a specific 
framework, considers FMT as substances of human origin,32 whereas some EU 
member states regulate FMT under tissues and cells standards and others as 
medicinal, non-ATMPs [advanced therapy medicinal products], or as foods.33 
 
The nonclinical to clinical translation for microbiome-based products provides 
specific development challenges not typically encountered with other types of 
regulated healthcare products.34 Given a large variety and mode of action, as 
well as the need for microbial characterization, a case-by-case product 
development approach is typical. Rousseau and colleagues35 have described a 
vast spectrum of available microbiome-adapted nonclinical models, some of 
which are already well developed and continuously improving. Moreover, the 
regulatory framework for computer-based, in silico modelling and simulation, is 
starting to evolve and will eventually provide additional “digital evidence” to 
complement nonclinical and clinical studies. Rousseau and colleagues had also 
reviewed the potential use of in silico analyses in the microbiome field to 
investigate the interactions and role of the host microbiome on the host 
health,36 explore the microbiomes’ impact on the immune system, or identify 
personalized microbiota.37,38 
 
Meeting the challenges of translating nonclinical models to the human situation, 
that is, moving models from bench to bedside, requires understanding of what 
determines a healthy microbiome, what a healthy reference microbiome is, and 
how microbiomes react to drugs and stimuli. Most drugs directly target a 
patient’s cells or tissues, whereas microbiome-based products aim to modify, 




are modified by, or interact with the patient’s microbiota. By the same token, 
microbiome‒drug interactions and the resulting clinical responses linked to 
different gut microbiomes composition must be considered.39 An integrative 
approach is advisable in regard to chemistry, manufacturing, and controls, or 
CMC, whereas nonclinical and clinical product development must align findings 
and increase their relevance toward expected human treatment outcomes.40 
 
The food- and nutrition-related regulatory science framework for microbiome-
based products is significantly less developed than it is for personalized, 
precision, or bespoke medicine. Beyond fulfilling potential novel food approval 
requirements for innovative components, “prebiotic,” “probiotic,” and 
“postbiotic” statements are considered implicit references to general, 
nonspecific benefits of the nutrient or food for overall good health or health-
related well-being. They face the challenge of being accompanied by a specific, 
authorized health claim in the EU.41,42 
 
The foremost mandate for regulatory science is to ensure consumer and patient 
safety in our volatile, uncertain, complex, ambiguous environment. Novel, 
rapidly evolving science and diagnostic technologies, of particular relevance for 
the microbiome, require regulatory science to enable a pragmatic shift of past 
paradigms.43 Indeed, as omics technologies blur the traditional segmentation 
between consumers (health) versus patients (disease), disease prevention 
versus treatment, and nutrition versus drug, the regulatory framework should 
adopt this development as part of a new concept that approaches health 
holistically. In addition, although it is necessary to address the increased 
complexity of understanding and defining “where health ends and disease 
starts,” practical solutions should include a certain level of uncertainty, while 
ensuring safety and efficacy of interventions.44 
 
It is a challenge to provide healthcare solutions as rapidly as possible to citizens 
who need them urgently and would otherwise suffer unduly. Meeting the 
challenge requires a pragmatic rethinking and refinement of healthcare 
development and access approaches, involving diverse stakeholders from 
science, the healthcare profession, and industry, as well as payers and 
politicians. Recognizing this raises the question of what policymaking would be 
required to ensure a clinically beneficial and cost-efficient healthcare 
environment for the individual and the population.45 
 
Innovating healthcare policy 
Schneeman46 has argued that, although science is necessary for developing 
policy, it is not always sufficient. For instance, challenges associated with 
disease prevention or global malnutrition problems will have to be addressed 
through multidisciplinary approaches. There have been multiple efforts to 
review current policies and the need to adapt to fast-moving, innovative areas, 
such as personalizing healthcare,47 making sense of dietary guidelines,48,49 
creating and improving the evidence for nutrition,50,51 and understanding and 
targeting the microbiome.52,53  
 




Given the developmental speed of new data and technologies, and the 
complexity and importance of nutrition products for life and healthcare, it might 
be necessary to factor in a certain amount of risk when building evidence for 
nutrition products ‒ as well as the microbiota.54,55 While justifying potential risk, 
the principle safety and utility of nutrition products for the prevention and 
management of diseases compared with other available healthcare options, 
cannot be overly emphasized. 
 
Key issues expected to be addressed by the European coordination and support 
action referred to previously in this article, are essential for society and 
necessitate sound and rapid regulatory answers. In addition to the question of 
what constitutes a healthy state microbiome, we need to understand how to 
define health and disease in general, and, in that context, how to define who is 
a consumer and who is a patient. The new tools in science, as well as societal 
needs, such as NCD prevention or healthcare cost efficiency, require deeper 
investigation, which could result in some existing models and paradigms being 
questioned and having to be re-conceptualized or revised.56 There is proven 
precedence in healthcare – for example, with the Orphan Disease Act – to 
create incentives to treat rare diseases, as with the development and approval 
pathways to respond to treatment challenges in the early days of the HIV/AIDS 
crisis, or with biotechnological versus small-entity chemical drugs.57 New tools, 
targets, and an increasing cost burden, require similar action as quickly as 
possible. 
 
The Organisation for Economic Co-operation and Development has clearly 
stated the key policy challenges for innovation in the microbiome through 
diet.58 There is accumulating scientific evidence that the gut microbiome can be 
altered to generate greater health and well-being, offer better protection and 
resilience against NCDs, and even cure conditions such as type 2 diabetes and 
Clostridium difficile infections. Yet, to lead to innovative applications, science 
and innovation policies must be improved in five areas:  
 
• science policy 
• enabling translational science 
• public‒private collaboration 
• regulatory frameworks  
• skills, communication, and public awareness 
 
The same principles should apply to the other microbiomes in and on the 
human body, even if less is known about them, compared with the gut, and they 
are not as widely researched. 
 
Hence, beyond continuing to corroborate the foundation of well-known, 
population-based approaches, establishing the right framework conditions is 
essential when targeting the microbiome as part of personalized and preventive 
healthcare. A reliable and trustworthy science base is a major criterion for 
healthcare systems to support novel interventions or to take up in novel dietary 
guidelines. These should be supported by regulatory systems that accept the 
concept of a continuum between health and disease and food or drug and 




address these issues with a holistic approach. Creating awareness and value for 
citizens and healthcare providers is essential. However, it is important to not 
encourage the “hype” currently associated with areas of personalized nutrition 




Given the strong evidence that microbiomes play an important role in human 
health and have clear links to many of the major NCDs, and possibly even in 
infectious diseases, it is of paramount importance that information is gathered, 
disseminated, and translated into policy solutions as quickly as possible. Due to 
their intrinsic complexities, these issues are best addressed through a well-
managed, multistakeholder approach. The approach should be global, as well as 
regional and local, where advisable. 
 
Multistakeholder campaigns60 
Changes in science and technology are moving at unprecedented speed. Science 
is entrenched in thematic “silos” and struggling to cope with change, but it is 
needed for guiding regulatory and policymaking decisions.61 The stakes are high 
for the ambitious goal of including the microbiome in our global healthcare 
approaches as soon as possible, and strengthening nutrition and personalized 
medicine as a beneficial and cost-effective way to prevent and/or treat NCDs. 




For sustained impact, a science-based, multistakeholder collaboration is the 
most promising and systematic way of finding comprehensive solutions to 
characterize the microbiota on a global scale and discern what determines a 
healthy microbiome in terms of aging, gender, and ethnicities. Given the 
enormity of the task and the many factors that can affect its trajectory, single-
sector or stakeholder actions are unlikely to effectively influence all aspects of 
microbiome research in a coordinated fashion.62,63 
 
Working together will maximize impact. Aligning goals, resources, and working 
in a coordinated manner, can multiply the impact of individual stakeholders. 
Exploring mutually beneficial linkages across stakeholders and programs can 
build organizational capacity. A multistakeholder approach, aligned with 
straightforward goals and a clear path to implementation, means pooling 
limited resources and allowing the collaboration to maximize financial and 
technical expertise. By working together, stakeholders can draw on collective 
core competencies to create a more comprehensive set of capabilities.64 
 
The multistakeholder initiatives outlined in the preceding section, “Innovating 
regulatory science,” provide insight into the state of research on the human 
microbiome and its links to health and certain diseases. In the best case 
scenario, they ultimately will establish a “community of practice” incorporating 
science, regulatory and industry experts, funders, and political leaders from 
around the globe, all addressing the need for standardization and agreeing on 
reference human microbiomes (in and on the human body) and how they relate 
to health, different disease areas, nutrition, gender differences, populations, 
and ethnicities. 
 
Key will be to translate this knowledge from bench to bedside, thereby ensuring 
that the human microbiome awareness and information will reach healthcare 
professionals and the broader audience for rapid implementation. The Optimal 
Nutrition Care for All, or ONCA, multistakeholder campaign, spearheaded by the 
European Nutrition for Health Alliance, showcases a successful way forward in 
its efforts to tackle the costly malnutrition epidemic by implementing routine 
nutrition risk screening, increasing education campaigns to raise public 
awareness, and implementing proper science-based nutrition care for patients 
in 18 countries.65,66 As an African proverb advocates: “If you want to go fast, go 
alone, if you want to go far, go together.”67 
 
Conclusion 
The human microbiota and microbiomes play a strategic role in general 
population-based approaches as well as personalizing health and disease 
management. New evidence and the scourge of NCDs are demanding diligent 
regulatory science and rapid policy action to translate knowledge and 
disseminate and implement solutions rapidly to consumers, patients, and 
healthcare providers. Given the intrinsic complexity of challenges, issues are 
best addressed by a well-orchestrated, multistakeholder approach. While 
multiple analytical approaches are currently used by researchers worldwide, 
establishing basic harmonized processes and standards to better compare and 
understand the baseline healthy microbiota is essential for developing 
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